

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-42) FLOTETUZUMAB

PRONUNCIATION floe" te tooz' ue mab

THERAPEUTIC CLAIM Treatment of hematologic malignancies

CHEMICAL NAMES

1. Immunoglobulin, anti-(human interleukin 3 receptor) (human-*Mus musculus* monoclonal light chain variable region fragment) fusion protein with peptide (synthetic linker) fusion protein with immunoglobulin, anti-(human CD3 antigen) (human-*Mus musculus* monoclonal heavy chain variable region fragment) fusion protein with peptide (synthetic linker) fusion protein with peptide (synthetic K-coil domain fragment), (249→241')-disulfide with immunoglobulin, anti-(human CD3 antigen) (human-*Mus musculus* monoclonal light chain variable region fragment) fusion protein with peptide (synthetic linker) fusion protein with immunoglobulin, anti-(human interleukin 3 receptor) (human-*Mus musculus* monoclonal heavy chain variable region fragment) fusion protein with peptide (synthetic linker) fusion protein with peptide (synthetic E-coil domain fragment)
2. Immunoglobulin bispecific variable fragments dual chain, anti-(human interleukin-3 receptor) and anti-(human CD3 antigen), human-mouse monoclonal antibody: [human-mouse V-KAPPA (*Mus musculus* IGKV8-19*01 (91%) –IGKJ2*03 (92%)) [12.3.9]]-(1-113)-fusion protein with triglycyl-seryltetraglycyl-[human-mouse V-GAMMA (*Mus musculus* IGHV10-1*02 (90%) –IGHJ3*01 (93%)) [8.10.16]]-(122-246)-fusion protein with diglycyl-cysteinyltriglycyl-(synthetic K-coil domain fragment)-(253-280) and [human-mouse V-LAMBDA (*Mus musculus* IGLV1*01 (81%) –IGLJ1*01 (100%)) [9.3.9]]-(1'-109')-fusion protein with tetraglycyl-seryltetraglycyl-[human-mouse V-GAMMA (*Homo sapiens* IGHV1-46*01 (84%) –IGHJ6*01 (91%)) [8.8.13]]-(119'-238')-fusion protein with diglycyl-cysteinyltriglycyl-(synthetic E-coil domain fragment)-(245'-272'); heterodimer (241'-249)-disulfide

STRUCTURAL FORMULA

Chain 1

DFVMTQSPDS	LAVSLGERVT	MSCKSSQSLL	NSGNQKNYLT	WYQQKPGQPP	50
KLLIYWASTR	ESGVPDRFSG	SGSGTDFTLT	ISSLQAEDVA	VYYCQNDYSY	100
PYTFGQGTKL	EIKGGGSGGG	GEVQLVESGG	GLVQPGGSLR	LSCAASGFTF	150
STYAMNWVRQ	APGKGLEWVG	RIRSKYNNYA	TYYADSVKDR	FTISRDDSKN	200
SLYLQMNSLK	TEDTAVYYCV	RHGNGNSYV	SWFAYWGQGT	LVTVSSGGCG	250
GGKVAALKEK	VAALKEKVAA	LKEKVAALKE			280

Chain 2

QAVVTQEPSL	TVSPGGTVTL	TCRSSTGAVT	TSNYANWVQQ	KPGQAPRGLI	50'
GGTNKRAPWT	PARFSGSLLG	GKAALTITGA	QAEDEADYYC	ALWYSNLWVF	100'
GGGTKLTVLG	GGGSGGGGEV	QLVQSGAELK	KPGASVKVSC	KASGYTFTDY	150'
YMKWVRQAPG	QGLEWIGDII	PSNGATFYNQ	KFKGRVTITV	DKSTSTAYME	200'
LSSLRSEDTA	VYYCARSHLL	RASWFAYWQQ	GTLVTVSSGG	CGGGEVAALE	250'
KEVAALEKEV	AALEKEVAAL	EK			272'

Disulfide bridges

22'-90' 23-94 140'-214' 143-219 241'-249

Modified residues



MOLECULAR FORMULA

C₂₆₁₈H₄₀₄₀N₇₀₄O₈₁₃S₁₆

MOLECULAR WEIGHT

58.9 kDa

TRADEMARK

None as yet

SPONSOR

MacroGenics, Inc.

CODE DESIGNATIONS

MGD006, S80880, RES234

CAS REGISTRY NUMBER

1664355-28-5

UNII

0AHT0IC02G

WHO NUMBER

10569

gbk